Imaging Lab realizes the convergence of Median's iCRO business unit, which uses image management to develop new cancer drugs, and its AI technology iBiopsy, which is used to develop software as a medical device, to target early-stage cancers, especially lung cancer.

Converging the businesses enables Median to leverage imaging data in conjunction with other clinical information and provide biopharmaceutical companies with tools for "go/no-go" decisions in trials, which aims to improve their success rates.

Furthermore, Imaging Lab will provide insight into the following:

• Selection of patients included in trials, especially inclusion of those diagnosed at early stages of disease
• Prediction of response to therapy
• Measurement of disease progression
• Evaluation of the safety of drug candidates

Median's Imaging Lab team will be present from 4-6 June at the American Society of Clinical Oncology (ASCO) annual conference in Chicago.

FDA debuts website for patient-reported cancer outcomes
The U.S. Food and Drug Administration (FDA) has unveiled Project Patient Voice, a new pilot program for communicating patient-reported outcomes from cancer...